Sionna Therapeutics, Inc. filed a Form 8-K on August 10, 2026, announcing topline data from its PreciSION CF Phase 2a proof-of-concept trial of SION-719 and its Phase 1 trial of SION-451-based proprietary dual combinations, along with a corporate update on next steps.

Key Highlights

  • Topline data released: Sionna Therapeutics announced topline data from both the PreciSION CF Phase 2a proof-of-concept trial of SION-719 and the Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects.
  • SION-719 not advancing: According to the filing, the company disclosed it is not advancing SION-719 as an add-on to standard of care.
  • Capital preservation: The company disclosed plans to preserve capital while evaluating next steps for its SION-451 dual combination program.
  • SION-719 context: The Phase 2a trial evaluated SION-719 when added to current standard of care for cystic fibrosis.
  • Signing authority: The filing was signed by Jennifer Fitzpatrick, Chief Legal Officer, on behalf of the registrant.

Sionna Therapeutics Discloses Trial Results and Program Strategy Update

On August 10, 2026, Sionna Therapeutics, Inc. (Nasdaq Global Market: SION) reported topline data from two clinical programs, according to the Form 8-K filing. The first was the PreciSION CF Phase 2a proof-of-concept trial, which evaluated SION-719 as an add-on to current standard of care. The second was a Phase 1 trial assessing SION-451-based proprietary dual combinations in healthy subjects.

Following these results, the company disclosed it is not advancing SION-719 as an add-on to standard of care. The filing also stated that Sionna Therapeutics plans to preserve capital while evaluating next steps for its SION-451 dual combination program. No specific financial figures, trial outcome metrics, or timelines were included in the body of the 8-K itself; the company noted that a press release containing the full announcement is attached as Exhibit 99.1 and incorporated by reference into the filing.

The company is incorporated in Delaware, is identified as an emerging growth company under applicable SEC rules, and has its principal executive offices located at 21 Hickory Drive, Suite 500, Waltham, MA 02451. The filing was signed by Chief Legal Officer Jennifer Fitzpatrick on August 10, 2026.

What Was Disclosed

Sionna Therapeutics filed an 8-K on August 10, 2026, disclosing topline clinical data for SION-719 and SION-451, announcing it will not advance SION-719 as an add-on therapy, and stating plans to preserve capital while evaluating next steps for the SION-451 program.